We engrafted mice with equal ratios of CD45.2 Jak2/Idh2-mutant cells and CD45.1 WT cells, and after the recipient mice developed MPN, they were treated with vehicle, the IDH2 inhibitor AG221, and/or the JAK kinase inhibitor ruxolitinib (INC18424). Here, IDH2 is linked to myeloproliferative disorder.